HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer

Hong sik Kim1,2, Ryul Kim1, Hye Ryeon Kim1, Hyun ji Jo1, Hana Kim1, Sang Yun Ha3, Joon Oh Park1, Young Suk Park1 and Seung Tae Kim1*

1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2 Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea, 3 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

HER2 aberrations have been reported as a novel biomarker in HER2-directed therapy or as a prognostic marker in various tumor types. However, in advanced biliary tract cancer (BTC), there have been few studies regarding HER2 aberrations as a biomarker. We analyzed 121 advanced BTC patients who had been treated with Gemcitabine/Cisplatin (GP) as a 1st line therapy between November 2019 and April 2021. Next-generation sequencing (NGS), namely, HER2 aberrations was performed in all patients. The TruSight™ Oncology 500 assay from Illumina was used for the NGS panel. Among 121 patients with advanced BTC, HER2 aberrations were observed in 18 patients (14.9%). For subtypes of HER2 aberrations, point mutation was observed in 5 patients (27.8%), gene amplification in 11 patients (61.1%), and both point mutation and gene amplification in 2 patients (11.1%). The frequency of HER2 aberrations was significantly different according to the primary tumor (p = 0.009). In gallbladder cancer, HER2 aberrations were observed at a relatively high frequency (36.4%). The tumor response to GP did not differ between patients with and without HER2 aberrations (33.3%, vs. 26.2%, respectively, p = 0.571). The median progression-free survival (PFS) to GP was 4.7 months (95% CI, 4.0 to 5.5 months) in patients with HER2 aberrations and 7.0 months (95% CI, 5.2 to 8.8 months) without HER2 aberrations (p = 0.776). The median overall survival (OS) was not reached and not reached in patients with and without HER2 aberrations (p = 0.739), respectively. The univariate analysis for PFS to GP and OS showed that HER2 aberrations were not an independent factor for survival. This study showed that the HER2 aberrations were observed in 14.9% of advanced BTC and were not an independent biomarker for survival.

Keywords: HER2, ERBB2, biliary tract cancer, next-generation sequencing, chemotherapy

INTRODUCTION

Biliary tract cancers (BTCs) are rare, aggressive, and heterogeneous malignancies (1, 2). Most patients present with advanced disease at the time of diagnosis. Palliative chemotherapy is the only treatment option for advanced BTC, and the gemcitabine plus cisplatin (GP) has been the standard of treatment as 1st line chemotherapy. However, the prognosis for these patients is poor, and median overall survival (OS) is less than one year with palliative chemotherapy (3–5).
Human epidermal growth factor receptor 2 (HER2) is associated with tumor proliferation by downstream signaling activation and is among the most investigated biomarker in various tumor types, namely, breast and gastric cancers (6, 7). HER2 aberrations play a role as predictive and prognostic biomarkers in various tumor types (8–11). Several studies also reported that the HER2 pathway could have a role in the development and growth of BTC (12–15) and HER2 overexpression and amplification were reported approximately 4–6% of BTC, 1–4% of intrahepatic cholangiocarcinoma, 4–9% of extrahepatic cholangiocarcinoma, and 9–14% of gallbladder cancer (11, 15, 16). Also, HER2-directed therapy has been developed in advanced BTCs (17–22). Several previous studies have assessed HER2 overexpression and amplification by immunohistochemistry (IHC) and focused only on HER2 directed therapy based on the results of IHC. However, most studies have focused only on the overexpression and/or amplification of HER2.

Recently, advances in whole-exome sequencing (WES) and next-generation sequencing (NGS) of multiple genes have defined the tumor biology of BTCs (23–25). Also, in previous studies, HER2 aberrations by NGS highly correlated with HER2 overexpression by IHC/FISH in various solid tumors (26–28). Currently, several clinical trials are evaluating the HER2-directed therapy based on HER2 aberrations detected by NGS in advanced BTCs (29, 30). However, in the era of NGS, there have been few reports on the role of HER2 aberrations, namely, gene mutation, gene amplification, and overexpression as a biomarker in advanced BTCs (31–34) and the role of HER2 aberrations to cytotoxic chemotherapy has not been evaluated yet. Therefore, we intended to explore the prevalence of HER2 aberrations using NGS in advanced BTCs and evaluate the role of HER2 aberrations as both a predictive factor for GP and a prognostic factor.

MATERIALS AND METHODS

Patients
We analyzed 121 advanced BTC patients who received gemcitabine and cisplatin (GP) as the 1st line treatment at the Samsung Medical Center, Korea, between November 2019 and April 2021. Molecular profiles, namely, HER2 aberrations, were available for all patients through NGS using the TruSight™ Oncology 500 assay (Illumina Inc., San Diego, CA, USA). The baseline clinicopathologic characteristics were collected for patients. The Institutional Review Board (IRB No. 2021-07-110) at the Samsung Medical Center approved this study and this retrospective analysis waived individual consent.

TruSight™ Oncology 500 Assay
The tumor samples were obtained at the time of diagnosis in advanced or metastatic BTCs and used formalin-fixed paraffin-embedded (FFPE) material. For DNA library preparation and enrichment, the TruSight™ Oncology 500 Kit was used following the manufacturer’s instructions. Post-enriched libraries were quantified, pooled, and sequenced on a NextSeq 500. The quality of the NextSeq 500 sequencing runs was assessed using the Illumina Sequencing Analysis Viewer. Sequencing data were analyzed with the TruSight Oncology 500 Local App Version 1.3.0.39. The TruSight™ Oncology 500 is a comprehensive tumor profiling assay and biomarkers, namely, single nucleotide variants (SNVs), copy number variants (CNVs), indels, fusions, and splice variants.

Treatmen Outcomes
All 121 patients were evaluated for clinical outcomes of objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) to gemcitabine and cisplatin as the 1st line treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 through computed tomography (CT). Also, overall survival (OS) was analyzed. PFS was defined as the time from the start of GP until the date of disease progression or death from any cause. OS was defined as the time from the start of GP until death from any cause. According to the RECIST, ORR was defined as the proportion of patients with a complete response (CR) or partial response (PR) to treatment and DCR was defined as the proportion of patients with a complete response (CR), partial response (PR) or stable disease (SD) to treatment.

Statistics
The cut-off date for data collection was April 30, 2021. Descriptive statistics were used to summarize patient and tumor characteristics and treatment history and were reported as proportions and medians. Data are presented as the number (%) for categorical variables. Correlations between HER2 aberrations and clinicopathologic features were analyzed by t-test or Fisher exact test. Survival analyses were performed using the Kaplan–Meier method, and differences were analyzed by log-rank test. Hazard ratios and corresponding 95% confidence intervals were calculated using the Cox proportional hazards model. Univariate analysis of predictive and prognostic factors was performed using Cox proportional hazards models for PFS and OS. IBM SPSS Statistics 25 was used for statistical analysis.

RESULTS

Patient Characteristics and HER2 Aberrations
All 121 patients were analyzed in this study. Of these, 18 (14.9%) had tumors with HER2 aberrations. HER2 aberrations were found in 5.8% (3/52) of intrahepatic cholangiocarcinoma patients, 13.9% (5/36) of extrahepatic cholangiocarcinoma patients, 36.4% (8/22) of gallbladder cancer patients, and 18.2% (2/11) of ampulla of Vater cancer patients. For subtypes of HER2 aberrations, point mutation was observed in 5 patients (27.8%), gene amplification in 11 patients (61.1%), and both point mutation and gene amplification in 2 patients (11.1%). Table 1 presents the clinical characteristics between patients with and without HER2 aberrations. HER2 aberrations were not
significantly correlated with any clinical baseline characteristics except the location of the primary tumor (p = 0.009).

**Association Between the Status of HER2 Aberrations and the Efficacy of Gemcitabine Plus Cisplatin**

We compared the tumor response, PFS, and OS to GP according to the status of HER2 aberrations. The ORR and DCR to GP were 33.3% (6/18, 95% CI 13.3–59.0) and 77.8% (14/18, 95% CI 52.3–93.6), respectively, in patients with HER2 aberrations and 26.2% (27/103, 95% CI 18.0–35.8) and 73.8% (76/103, 95% CI 64.2–82.0), respectively, in patients without HER2 aberrations. The ORR and DCR according to the status of HER2 aberrations were no significant differences (p = 0.571 and p = 1.000, respectively) (Table 2).

The median PFS to GP values was 4.7 months (95% CI, 4.0 to 5.5 months) and 7.0 months (95% CI, 5.2 to 8.8 months) in patients with and without HER2 aberrations, respectively (p = 0.776) (Figure 1).

The median OS was not reached in patients with HER2 aberrations and not reached in patients without HER2 aberrations (p = 0.739) (Figure 2).

**HER2 Aberrations—Univariate Analysis for Survivals**

We conducted univariate analyses for PFS to GP and OS to evaluate the role of HER2 aberrations as an independent biomarker (Table 3). Univariate analysis for PFS to GP showed that grade of differentiation (poorly differentiated vs. well/moderate differentiated), disease stage (metastasis vs. locally advanced), and the number of metastatic sites (≤2 vs. 2<) were significant independent factors; however, HER2 aberrations were not.

Also, HER2 aberrations were not an independent factor in univariate analysis for OS. We additionally conducted survival

---

**Table 1 | Baseline patient characteristics.**

|                     | HER2 (−) (n = 103) | HER2 (+) (n = 18) | p-value |
|---------------------|--------------------|-------------------|---------|
| Median age (range), years | 64 (47–79)         | 67 (33–82)        | 0.580   |
| Age 65+ years, n (%)  | 58 (56.3%)         | 8 (44.4%)         | 0.499   |
| Sex, n (%)           | Male 68 (66.0%)    | 10 (55.6%)        | 0.556   |
|                     | Female 35 (34.0%)  | 8 (44.4%)         |         |
| Tumor site, n (%)    | Intrahepatic 49 (47.6%) | 3 (16.7%)      | 0.009   |
|                     | Extrahepatic 31 (30.1%) | 5 (27.8%)       |         |
|                     | Gallbladder 14 (13.6%) | 8 (44.4%)        |         |
|                     | Ampulla of Vater 9 (8.7%) | 2 (11.1%)      |         |
| Grade of differentiation, n (%) | Poorly 29 (28.2%) | 4 (22.2%)        |         |
|                     | Well/Moderate 67 (65.0%) | 13 (72.2%)      |         |
|                     | Unknown 7 (6.8%)   | 1 (5.6%)          |         |
| Disease stage, n (%) | Metastasis 77 (74.8%) | 15 (83.3%)       | 0.628   |
|                     | Locally advanced 26 (25.2%) | 3 (16.7%)      |         |
| No. of metastatic sites, n (%) | ≤2 90 (87.4%) | 15 (83.3%)       | 0.928   |
|                     | 2< 13 (12.6%)      | 3 (16.7%)         |         |
| Metastatic sites, n (%) | Abdominal lymph node (M1) 45 (43.7%) | 10 (55.6%) |         |
|                     | Liver 41 (39.8%)   | 8 (44.4%)         |         |
|                     | Peritoneum 20 (19.4%) | 4 (22.2%)        |         |
|                     | Lung 6 (5.8%)      | 1 (5.6%)          |         |
|                     | Bone 4 (3.9%)      | 1 (5.6%)          |         |
|                     | Others 17 (16.5%)  | 8 (53.3%)         |         |

**Table 2 | Objective response rate to chemotherapy.**

|                      | HER2 aberrations (−) (n = 103) | HER2 aberrations (+) (n = 18) | p-value |
|----------------------|-------------------------------|-------------------------------|---------|
| Complete response    | 2 (1.9%)                      | 1 (5.6%)                      |         |
| Partial response     | 25 (24.3%)                    | 5 (27.8%)                     |         |
| Stable disease       | 49 (47.6%)                    | 8 (44.4%)                     |         |
| Progressive disease  | 14 (13.6%)                    | 1 (5.6%)                      |         |
| Not evaluable        | 13 (12.6%)                    | 3 (16.7%)                     |         |
| Objective response rate | 27 (26.2%)  | 6 (33.3%)                     | 0.571   |
| Disease control rate | 78 (73.8%)                    | 14 (77.8%)                    | 1.000   |
analyses for PFS and OS according to HER2 amplification. HER2 amplification also was not an independent factor in univariate analysis for PFS (p = 0.322) and OS (p = 0.168).

DISCUSSION

In our study, we identified that the prevalence of HER2 aberrations and the frequency of HER2 aberrations were significantly different according to the primary tumor, which was consistent with previous studies (16, 23, 35). Between the status of HER2 aberrations and treatment outcomes to GP, including ORR, DCR, and PFS were no significant differences. Also, HER2 aberrations were not an independent biomarker for PFS to GP and OS in univariate analysis. Because most clinical trials of HER2 targeted therapy included HER2 amplified BTCs, we additionally evaluate the role of HER2 amplification as a prognostic biomarker. However, HER2 amplification was not an independent biomarker for OS.

Recently, one study described genomic characteristics focusing on the ERBB/EGFR pathway in BTC using NGS. The prevalence of HER2 aberrations by NGS was 13.9% in 1,863 BTC patients from Western countries; of these, 6.2% were point mutation, 6.8% were amplification, and 0.9% were both point mutation and amplification, which was consistent with our results (14.9% in 121 patients) (16). However, that study did not evaluate the role of HER2 aberrations as predictive and prognostic biomarkers.

The role of HER2 aberrations as a predictive and prognostic biomarker in advanced BTC to palliative chemotherapy has not previously been elucidated. One study reported that HER2 expression by IHC represented an independent poor prognostic factor in patients with BTC treated with curative surgery (31). That study evaluated the relationship between HER2 expression by IHC and survival in 100 patients with radically resected BTC. However,
studies of neoadjuvant chemotherapy have been reported (44). Inconclusive, previous studies have reported HER2 overexpression as a biomarker in the setting of neoadjuvant chemotherapy.

Further studies are needed to evaluate the aberrations of HER2 as a novel biomarker by NGS in advanced BTC to palliative chemotherapy. Although our study focused only on the role of HER2 aberrations as a biomarker in the setting of neoadjuvant chemotherapy.

Optiopn for patients with curative intended surgery and a well clinical trial.

Although the role of HER2 in BTC patients is inconsistent and inconclusive, previous studies have reported HER2 overexpression by IHC as a predictive and prognostic biomarker. Recently, in the era of NGS, clinical trials with HER2 targeting therapy included HER2 aberrations by NGS. Therefore, we reviewed the prevalence of HER2 aberrations using NGS in advanced BTCs and a new perspective which was a prognostic and predictive role of HER2 aberrations by NGS in advanced BTCs.

The best of our knowledge, ours is the first study evaluating relationships between HER2 aberrations and GP, which is the current standard chemotherapy. We found that HER2 aberrations identified through NGS did not have a predictive or prognostic role on the standard first-line chemotherapy in advanced BTC.

This study has limitations. First, this study had a small sample size, was retrospective in nature, and utilized a heterogeneous population, which may lead to bias. However, the biliary tract cancers were a rare orphan disease. Especially, the acquisition of tumor-sample in biliary tract cancers is very difficult to work. This study tried to conduct a molecular study in biliary tract cancer. Second, only Asian patients with BTC were analyzed in the study, limiting the generalizability because of differences in relationships between HER2 aberrations and GP, which is the current standard chemotherapy. We found that HER2 aberrations identified through NGS did not have a predictive or prognostic role on the standard first-line chemotherapy in advanced BTC.

This study tried to conduct a molecular study in biliary tract cancer. Second, only Asian patients with BTC were analyzed in the study, limiting the generalizability because of differences in molecular profiles and clinical features between Western and Eastern patients with BTC. Third, the study included various types of HER2 aberrations, making it difficult to draw definite conclusions. Therefore, findings for the HER2 aberrations as a novel biomarker in this study should be interpreted with caution.

Further prospective clinical trials are required to determine whether HER2 aberrations could be a novel predictive or prognostic biomarker in BTC.

In conclusion, this retrospective study evaluated the prevalence of HER2 aberrations in BTC and the relationship between HER2 aberrations and clinical outcomes after cytotoxic chemotherapy. Our results suggest that HER2 aberrations in advanced BTC did not have a predictive or prognostic role on the standard first-line chemotherapy in advanced BTC.

**TABLE 3 | Univariate analysis of progression-free survival and overall survival after gemcitabine/cisplatin.**

|                          | Progression-free survival | Overall survival |
|--------------------------|---------------------------|-----------------|
|                          | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Age                      |             |         |             |         |
| <65 years                | 1           | 0.288   | 1           | 0.727   |
| ≥65 years                | 1.29 (0.81–2.07) |        | 1.12 (0.59–2.15) |        |
| Sex                      |             |         |             |         |
| Male                     | 1           | 0.139   | 1           | 0.010   |
| Female                   | 0.69 (0.43–1.12) |        | 0.35 (0.16–0.78) |        |
| Tumor site               |             |         |             |         |
| Intrahepatic             | 1           | 0.395   | 1           | 0.097   |
| Extrahepatic             | 0.89 (0.51–1.56) |        | 0.75 (0.36–1.57) |        |
| Gallbladder              | 0.82 (0.44–1.54) |        | 0.54 (0.20–1.44) |        |
| Ampulla of Vater         | 0.46 (0.19–1.12) |        | 0.07 (0.02–1.20) |        |
| Grade of differentiation |             |         |             |         |
| Poorly                   | 0.014       |        | 1           | 0.012   |
| Well/Moderate            | 0.53 (0.32–0.88) |        | 0.42 (0.22–0.83) |        |
| Disease stage            |             |         |             |         |
| Metastasis               | 1           | 0.006   | 1           | 0.142   |
| Locally advanced         | 0.27 (0.11–0.69) |        | 0.34 (0.08–1.43) |        |
| No. of metastatic sites  |             |         |             |         |
| ≥2                      | 1           | 0.004   | 1           | 0.001   |
| <2                      | 2.14 (1.27–3.62) |        | 3.63 (1.87–7.03) |        |
| HER2 aberrations         |             |         |             |         |
| Negative                 | 1           | 0.771   | 1           | 0.739   |
| Positive                 | 1.10 (0.58–2.11) |        | 1.16 (0.48–2.79) |        |

**Notes:**

- HR, hazard ratio; CI, confidence interval.
- **HER2** human epidermal growth factor receptor 2; **GP** grade of differentiation.
not have a prognostic or predictive biomarker in the first line standard cytotoxic chemotherapy (GP).

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because of the privacy restrictions at Samsung Medical Centre. Requests to access the datasets should be directed to shty1@skku.edu.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board (IRB no. 2021-07-110) of Samsung Medical Centre.

REFERENCES

1. Hong S, Won YJ, Park YR, Kong HJ, Lee ES. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res Treat (2020) 52(2):335–50. doi: 10.4143/crct.2020.206
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590
3. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-Line Chemotherapy in Advanced Biliary Cancer: A Systematic Review. Ann Oncol (2014) 25(12):2328–38. doi: 10.1093/annonc/mdu162
4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthonaye A, Maraveyas A, et al. Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer. N Engl J Med (2010) 362(14):1273–81. doi: 10.1056/NEJMoA0908721
5. Eckel F, Brunner T, Jelic S. Biliary Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2011) 22:v404–4. doi: 10.1093/annonc/mdr357
6. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 2014:852748. doi: 10.1155/2014/852748
7. Yarden Y, Slawkowski MX. Untangling the ErbB Signalling Network. Nat Rev Mol Cell Biol (2002) 3(2):127–37. doi: 10.1038/35025073
8. Baselga J, Swain SM. Novel Anticancer Targets: Revisiting ERBB2 and Discovering ERBB3. Nat Rev Cancer (2009) 9(7):463–75. doi: 10.1038/nrc2665
9. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenetic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomical Sites of Origin. Oncologist (2015) 20(1):7–12. doi: 10.1634/theoncologist.2014-0234
10. Roskoski Jr. The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer. Pharmacol Res (2014) 79:34–74. doi: 10.1016/j.phrs.2013.11.002
11. Yan M, Schweaderle M, Arguello D, Mills SZ, Gatalica Z, Kurzrock R. HER2 Expression Status in Diverse Cancers: Review of Results From 37,992 Patients. Cancer Metastasis Rev (2015) 34(1):157–64. doi: 10.1007/s10555-015-9552-6
12. Kiguchi K, Carbajal S, Chan K, Beltran L, Rufino L, Shen J, et al. Constitutive Expression of ErbB-2 in Gallbladder Epithelium Results in Development of Adenocarcinoma. Cancer Res (2001) 61(19):6971–6.
13. Pellat A, Vaquero J, Fouassier L. Role of ErbB/HER Family of Receptor Tyrosine Kinases in Cholangiocyte Biology. Hepatology (2018) 67(2):76–73. doi: 10.1002/hep.29350
14. Treekkitkarnmongkol W, Suthipongchaisri T. High Expression of ErbB2 Contributes to Cholangiocarcinoma Cell Invasion and Proliferation Through AKT/P70s6k. World J Gastroenterol (2010) 16(32):4047–54. doi: 10.3748/wjg.v16.i32.4047
15. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, et al. EGFR and HER2 Expression in Advanced Biliary Tract Cancer. World J Gastroenterol (2009) 15(36):4511–7. doi: 10.3748/wjg.15.4511

AUTHOR CONTRIBUTIONS

Conception and design: HoK, SK. Provision of study materials or patients: HoK, SH, JP, YP, SK. Collection and assembly of data: HoK, RK, HRK, HJ, HaK, SK. Data analysis and interpretation: HoK, SK. Manuscript writing: HoK, SK. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

ACKNOWLEDGMENTS

A grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) supported this research and the Ministry of Health & Welfare, Republic of Korea, funded (grant number: HR20C0025).

16. Jacobi O, Ross JS, Goshen-Lago T, Haddad R, Moore A, Sulkes A, et al. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncol Res Treat (2021) 44(1):20–7. doi: 10.1159/000519191
17. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, et al. A Phase II Study of Lapatinib in Patients With Advanced Biliary Tree and Hepatocellular Cancer. Cancer Chemother Pharmacol (2009) 64(4):777–83. doi: 10.1002/SCOBO-0.09297-7
18. Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, et al. Overexpression and Gene Amplification of EGFR, HER2, and HER3 in Biliary Tract Carcinomas, and the Possibility for Therapy With the HER2-Targeting Antibody Pertuzumab. J Gastroenterol (2015) 50(4):467–79. doi: 10.1007/s10555-014-0984-5
19. Law LY. Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Cholangiocarcinoma. J Clin Oncol (2012) 30(27):c271–3. doi: 10.1200/jco.2012.32.061
20. Jave M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, et al. HER2/neu-Directed Therapy for Biliary Tract Cancer. J Hematol Oncol (2015) 8:58. doi: 10.1186/s13045-015-0155-5
21. Jave M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George R, et al. Pertuzumab and Trastuzumab for HER2-Positive, Metastatic Biliary Tract Cancer (MyPathway): A Multicentre, Open-Label, Phase 2a, Multiple Basket Study. Lancet Oncol (2021) 22(9):1290–300. doi: 10.1016/s1470-2045(21)00336-3
22. Rizzo A, Frega G, Ricci AD, Palloni A, Abatti F, DEL S, et al. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. In Vivo (2020) 34(2):479–88. doi: 10.21873/invivo.11798
23. Jain A, Kwong LN, Jave M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol (2016) 17(11):58. doi: 10.1007/s11864-016-0432-2
24. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation Profiling in Cholangiocarcinoma: Diagnostic and Therapeutic Implications. PLoS One (2014) 9(12):e115383. doi: 10.1371/journal.pone.0115383
25. Kayhanian H, Smyth EC, Braconi C. Emerging Molecular Targets and Therapy for Cholangiocarcinoma. World J Gastrointest Oncol (2017) 9(7):268–80. doi: 10.4251/wjgi.v9.i7.268
26. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, et al. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol (2019) 3:PO.18.00345. doi: 10.1200/po.18.00345
27. Cenaj O, Ligon AH, Hornick JL, Sholl LM. Detection of ERBB2 Amplification Status: Clinical Validation in the Context of a
Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. J Mol Diagn (2017) 19(2):244–54. doi: 10.1016/j.jmoldx.2016.09.010

29. Yarlagadda B, Kootstra V, Ritter A, Shahriehan F, Kasi PM. Trastuzumab and Pertuzumab in Circulating Tumor DNA ERBB2-Amplified HER2-Positive Refractory Cholangiocarcinoma. NPJ Precis Oncol (2019) 3:19. doi: 10.1038/s41698-019-0091-4

30. Mondaca S, Razavi P, Xu C, Offin M, Myers M, Scaltriti M, et al. Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol (2019) 3:PO.19.00223. doi: 10.1200/po.19.00223

31. Vivaldi C, Fornaro L, Ugolini C, Niccoli C, Musettini G, Pecora I, et al. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. Oncologist (2020) 25(10):886–93. doi: 10.1634/theoncologist.2019-0922

32. García P, Lamerca A, Díaz J, Carrera E, Roa JC. On Behalf of the European-Latin American Escalon Consortium. Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. Cancers (Basel) (2020) 12(12):3670. doi: 10.3390/cancers12123670

33. Singh A, Mishra PK, Saluja SS, Talikoti MA, Kirtani P, Najmi AK. Prognostic Significance of HER-2 and P53 Expression in Gallbladder Carcinoma in North Indian Patients. Oncology (2016) 91(6):354–60. doi: 10.1159/000450999

34. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, et al. Next-Generation Sequencing Survey of Biliary Tract Cancer Reveals the Association Between Tumor Somatic Variants and Chemotherapy Resistance. Cancer (2016) 122(3):3657–66. doi: 10.1002/cncr.30247

35. Galdy S, Lamarca A, McNamara MG, Hubner RA, Cellà CA, Fazio N, et al. HER2/HER3 Pathway in Biliary Tract Malignancies; Systematic Review and Meta-Analysis: A Potential Therapeutic Target? Cancer Metastasis Rev (2017) 36(1):141–57. doi: 10.1007/s10555-016-9645-x

36. Ogo Y, Nio Y, Yano S, Toga T, Koike M, Hashimoto K, et al. Immunohistochemical Expression of HER-1 and HER-2 in Extrahepatic Biliary Carcinoma. Anticancer Res (2006) 26(1b):763–70.

37. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II Study of Erlolatinib in Patients With Advanced Biliary Cancer. J Clin Oncol (2006) 24(19):3069–74. doi: 10.1200/jco.2005.05.3579

38. Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may Not be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study With Laptatinib. Oncology (2012) 82(3):175–9. doi: 10.1159/000336488

39. Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, et al. Panitumumab in Combination With Gemcitabine and Oxaliplatin Does Not Prolong Survival in Wild-Type KRAS Advanced Biliary Tract Cancer: A Randomized Phase 2 Trial (Vecti-BIL Study). Cancer (2016) 122(4):574–81. doi: 10.1002/cncr.29778

40. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamanull D, Kacirek K, et al. Cetuximab, Gemcitabine, and Oxaliplatin in Patients With Unresectable Advanced or Metastatic Biliary Tract Cancer: A Phase 2 Study. Lancet Oncol (2010) 11(12):1142–8. doi: 10.1016/s1470-2045(10)70247-3

41. Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 With Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov (2020) 10(5):688–701. doi: 10.1158/2159-8290.Cd-19-1014

42. Bang JY, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, et al. First-In-Human Phase 1 Study of Margetuximab (MGAH22), an Fc-Modified Chimeric Monoclonal Antibody, in Patients With ERBB2-Positive Advanced Solid Tumors. Ann Oncol (2017) 28(4):855–61. doi: 10.1093/annonc/mdx002

43. Meric-Bernstam F, Hanna DL, El-Khoueiry AB, Kang Y-K, Oh D-Y, Charise JM, et al. Zanidatamab (ZW25) in HER2-Positive Biliary Tract Cancers (BTCs): Results From a Phase I Study. J Clin Oncol (2021) 39(3_suppl):299. doi: 10.1200/jco.2021.39.3_suppl.299

44. Nara S, Esaki M, Ban D, Takamori T, Shimada K, Ioka T, et al. Adjuvant and Neoadjuvant Therapy for Biliary Tract Cancer: A Review of Clinical Trials. Jpn J Clin Oncol (2020) 50(12):1353–63. doi: 10.1093/jjco/hyaa170

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kim, Kim, Kim, Jo, Kim, Ha, Park, and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.